BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Specialised Therapeutics announces approval of Global Sarcoma Therapy in Thailand

November 16, 2026 | News

Approval of YONDELISÂ® (trabectedin) by the Thai FDA for patients who have failed prior treatment with anthracyclines and ifosfamide or for those who are unsuited to receive these agents



Singapore-based Specialised Therapeutics has announced that the Thailand Food and Drug Administration has approved YONDELIS® (trabectedin) on for the treatment of adult patients with advanced soft tissue sarcoma (STS).

The regulatory approval grants access to YONDELIS for patients who have failed prior treatment with anthracyclines and ifosfamide, or for those who are unsuited to receive these agents.

YONDELIS is an established antineoplastic agent originally derived from the sea squirt (*Ecteinascidia turbinata*). It exerts the anti-tumour effect by binding to the minor groove of DNA, disrupting the cell cycle and preventing cancer cells from multiplying.

STS is a rare and complex disease. In Thailand, the age-standardised incidence rate of STS is 2.14 per 100,000 person-years, which is relatively low compared to Western nations. The most frequently reported histological subtypes among Thai patients are unspecified sarcoma (24.8%), leiomyosarcoma (19.0%), and liposarcoma (11.4%). While current healthcare treatments yield a five-year relative survival rate of 62.6% for soft tissue sarcoma in Thailand, there remains a critical need for advanced, specialised therapies for patients whose cancer progresses or relapses after initial care.

Under an exclusive licensing agreement with global partner PharmaMar S.A., Specialised Therapeutics will be responsible for all regulatory, commercialisation, distribution, and medical engagement operations for YONDELIS in Thailand.